期刊
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
卷 34, 期 5, 页码 281-289出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1533317519843720
关键词
Intravenous immunoglobulin; Alzheimer's disease; meta-analysis; systematic review
资金
- Intramural Research Program of the National Institutes of Health, NIH
- NATIONAL INSTITUTE ON AGING [ZIAAG000975] Funding Source: NIH RePORTER
Aim: To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD). Materials and Methods: We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Results: Five placebo-controlled trials were included in the meta-analysis. Compared to placebo, IVIg 0.2 and 0.4 g/kg once every two weeks did not change ADAS-Cog score (weighted mean difference: 0.37, 95% confidence interval: -1.46 to 2.20 and 0.77, -1.34 to 2.88, respectively). Furthermore, except for an increase in the incidence of rash, IVIg did not affect the incidence of other adverse events. Conclusion: IVIg, albeit safe, is inefficacious for treatment of patients with AD. Future trials targeting earlier stages of disease or applying different dosing regimens may be warranted to clarify its therapeutic potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据